EPISODE · Nov 14, 2025 · 7 MIN
IMvigor011: A Phase 3 Trial of ctDNA-Guided Adjuvant Atezolizumab versus Placebo in MIBC - report from ESMO 2025
from Medical Digest & Congress Report · host Medical Congress News
Professor Thomas B. Powles discuss the results from IMvigor011, a phase 3 trial of ctDNA-guided adjuvant atezolizumab versus placebo in muscle invasive bladder cancer were presented at the ESMO Congress 2025.Video: https://medicaldigest.org/scientific-contents/interview:imvigor011-phase-3-trial-ctdna-guided-adjuvant-atezolizumab-versus-placebo-mibc
Embed this episode
Ready to play
IMvigor011: A Phase 3 Trial of ctDNA-Guided Adjuvant Atezolizumab versus Placebo in MIBC - report from ESMO 2025
No transcript for this episode yet
Similar Episodes
No similar episodes found.